1Q 2017 PERFORMANCE

FINANCIAL RESULTS BUSINESS HIGHLIGHTS

SALES WORLDWIDE 1 Strategic Actions Shape the Company

for Continued Long-term Success

+3.2% $
6.3BN ACQUIRED ST. JUDE MEDICAL
ON COMPARABLE
OPERATIONAL BASIS*
ABBOTT NOW HAS
LEADERSHIP
BUSINESS SEGMENT SALES POSITIONS
IN ALL BUSINESSES
DIAGNOSTICS NUTRITION
Medical Devices & Diagnostics Innovation
NEW U.S. PRODUCTS
Patients with the Assurity MRI pacemaker and the

$
1.2BN $
1.6BN
Tendril MRI pacing lead will have the ability to undergo
full body magnetic resonance imaging (MRI) scans, if required.
Ensite Precision cardiac mapping system, which helps
physicians more effectively treat patients experiencing
arrhythmias in the heart.
ESTABLISHED
MEDICAL DEVICES PHARMACEUTICALS NEW FREESTYLE LIBRE DATA
Real-world data 2 from 50,000 FreeStyle Libre3 users revealed
a higher rate of glucose testing. The data show that higher rates
of testing were found to be strongly associated with improved
glucose control.

$
2.4BN $
950MM ALINITY SYSTEMS
Designed to increase efficiency and provide quality results,
four Alinity systems were launched internationally for clinical
chemistry, immunoassay, blood screening and point of care.**

*Comparable operational results are non-GAAP and include the prior year results for St. Jude Medical, and exclude the impact of exchange and prior and current year results for divested businesses. For full financial data and
reconciliation of non-GAAP measures, please see our press release dated April 19, 2017.
**Not yet available in the United States.
1
Reported sales +29.7%
2
Data on file. Dunn T, Xu Y, Hayter G; Evidence of a Strong Association Between Frequency of Flash Glucose Monitoring and Glucose Control Measures During Real-World Usage.
3
Pending FDA approval. Not available for sale in the United States.

FORWARD-LOOKING STATEMENTS
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbotts operations
are discussed in Item 1A, Risk Factors to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2016, and are incorporated by reference. Abbott undertakes no obligation to release
publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

ABBOTT.COM @ABBOTTNEWS; @ABBOTTGLOBAL ABBOTTGLOBAL ABBOTT